# US 2020/0392228 A1 · MAdCAM TARGETED IMMUNOTOLERANCE

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2020/0392228 A1
- Document ID: US20200392228A1
- Status: Published application
- Kind: A1
- Application number: 16/878,946
- Filed: 2020-05-20
- Published: 2020-12-17
- Earliest claimed: 2019-05-20
- Assignees: Pandion Therapeutics, Inc.
- Applicants: Pandion Therapeutics, Inc.
- Inventors: Nathan Higginson-Scott; Joanne L. Viney; Kevin Lewis Otipoby; Jyothsna Visweswaraiah; Salvatore Alioto; Lindsay J. Edwards; Erik Sampson; Jacob Glanville; David Maurer; Sarah Ives; Christina Pettus; Lauren Schwimmer
- Web page: https://patentgrep.com/patent/US20200392228A1

## CPC

- C07K 16/2803: {against the immunoglobulin superfamily}
- C07K 16/2818: {against CD28 or CD152}
- A61K 2039/505: {comprising antibodies}
- C07K 2317/31: multispecific
- C07K 2317/33: Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
- C07K 2317/51: Complete heavy chain or Fd fragment, i.e. VH + CH1
- C07K 2317/526: CH3 domain
- C07K 2317/565: Complementarity determining region [CDR]
- C07K 2317/60: characterized by non-natural combinations of immunoglobulin fragments
- C07K 2317/64: comprising a combination of variable region and constant region components
- C07K 2317/75: Agonist effect on antigen
- C07K 2317/76: Antagonist effect on antigen, e.g. neutralization or inhibition of binding
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

Methods and compounds for conferring site-specific or local immune privilege, such as targeting to a cell expressing MAdCAM.

## Claims

### Claim at position 1

1-116. (canceled)

### Claim 117

An antibody that binds to MAdCAM, wherein the antibody comprises one or more sequence as provided in Table 6 or Table 7.

### Claim 118 (depends on 117)

The antibody of claim 117, or antigen binding fragment thereof, wherein the antibody, or antigen binding fragment thereof, comprises:
(i) a heavy chain variable region comprising heavy chain CDR1, CDR2, and CDR3 sequences, wherein the heavy chain CDR1 sequence has the amino acid sequence of any of the CDR1 sequences set forth in Table 6 or Table 7; the heavy chain CDR2 has the amino acid sequence of any of the CDR2 sequences set forth in Table 6 or Table 7, and the heavy chain CDR3 has the amino acid sequence of any of the CDR3 sequences set forth in Table 6 or Table 7, or variants of any of the foregoing; and
(ii) a light chain variable region comprising light chain CDR1, CDR2, and CDR3 sequences, wherein the light chain CDR1 sequence has the amino acid sequence of any of the CDR1 sequences set forth in Table 6 or Table 7; the light chain CDR2 has the amino acid sequence of any of the CDR2 sequences set forth in Table 6 or Table 7, and the light chain CDR3 has the amino acid sequence of any of the CDR3 sequences set forth in Table 6 or Table 7, or variants of any of the foregoing.

### Claim 119 (depends on 117)

The antibody of claim 117, or antigen binding fragment thereof, wherein the antibody, or antigen binding fragment thereof, comprises:
i) a heavy chain variable region comprising heavy chain CDR1, CDR2, and CDR3 sequences, wherein the heavy chain CDR1 sequence has the amino acid sequence of SEQ ID NOs: 90, 359, or 135; the heavy chain CDR2 has the amino acid sequence of SEQ ID NOs: 91, 170, or 381, and the heavy chain CDR3 has the amino acid sequence of SEQ ID NOs: 92, 360, or 382, or variants of any of the foregoing; and
(ii) a light chain variable region comprising light chain CDR1, CDR2, and CDR3 sequences, wherein the light chain CDR1 sequence has the amino acid sequence of SEQ ID NOs: 93, 361, or 383; the light chain CDR2 has the amino acid sequence of SEQ ID NOs: 87, 362, or 384, and the light chain CDR3 has the amino acid sequence of SEQ ID NOs: 94, 363, or 385, or variants of any of the foregoing.

### Claim 120 (depends on 117)

The antibody of claim 117, or antigen binding fragment thereof, wherein the antibody, or antigen binding fragment thereof, comprises:
i) a heavy chain variable region comprising heavy chain CDR1, CDR2, and CDR3 sequences, wherein the heavy chain CDR1 sequence has the amino acid sequence of SEQ ID NO: 90, the heavy chain CDR2 has the amino acid sequence of SEQ ID NO: 91, and the heavy chain CDR3 has the amino acid sequence of SEQ ID NO: 92, or variants of any of the foregoing; and a light chain variable region comprising light chain CDR1, CDR2, and CDR3 sequences, wherein the light chain CDR1 sequence has the amino acid sequence of SEQ ID NO: 93, the light chain CDR2 has the amino acid sequence of SEQ ID NO: 87, and the light chain CDR3 has the amino acid sequence of SEQ ID NO: 94, or variants of any of the foregoing;
ii) a heavy chain variable region comprising heavy chain CDR1, CDR2, and CDR3 sequences, wherein the heavy chain CDR1 sequence has the amino acid sequence of SEQ ID NO: 135, the heavy chain CDR2 has the amino acid sequence of SEQ ID NO: 381, and the heavy chain CDR3 has the amino acid sequence of SEQ ID NO: 382, or variants of any of the foregoing; and a light chain variable region comprising light chain CDR1, CDR2, and CDR3 sequences, wherein the light chain CDR1 sequence has the amino acid sequence of SEQ ID NO: 383, the light chain CDR2 has the amino acid sequence of SEQ ID NO: 384, and the light chain CDR3 has the amino acid sequence of SEQ ID NO: 385, or variants of any of the foregoing; or
iii) a heavy chain variable region comprising heavy chain CDR1, CDR2, and CDR3 sequences, wherein the heavy chain CDR1 sequence has the amino acid sequence SEQ ID NO: 359, the heavy chain CDR2 has the amino acid sequence of SEQ ID NO: 170, and the heavy chain CDR3 has the amino acid sequence of SEQ ID NO:360, or variants of any of the foregoing; and a light chain variable region comprising light chain CDR1, CDR2, and CDR3 sequences, wherein the light chain CDR1 sequence has the amino acid sequence of SEQ ID NO: 361, the light chain LCDR2 has the amino acid sequence of SEQ ID NO: 362, and the light chain CDR3 has the amino acid sequence of SEQ ID NO: 363, or variants of any of the foregoing.

### Claim 121 (depends on 118)

The antibody claim 118, wherein the heavy chain variable region and the light chain variable region are in a scFv format.

### Claim 122 (depends on 117)

The antibody of claim 117, or antigen binding fragment thereof, wherein the antibody comprises a VK sequence as shown in Table 7 and/or a VH sequence as shown in Table 7.

### Claim 123 (depends on 122)

The antibody of claim 122, wherein the VK sequence comprises a sequence of SEQ ID NOs: 415, 592, or 600 and the VH sequence comprises a sequence of SEQ ID NOs: 414, 591, or 599

### Claim 124 (depends on 122)

The antibody of claim 122, or antigen binding fragment thereof, wherein the antibody comprises a:
VK having a sequence of SEQ ID NO: 415, or a variant thereof, and a VH having a sequence of SEQ ID NO: 414, or a variant thereof;
a VK of SEQ ID NO: 592, or a variant thereof and a VH sequence of SEQ ID NO: 591, or a variant thereof; or
a VK of SEQ ID NO: 600, or a variant thereof, and a VH sequence of SEQ ID NO: 599, or a variant thereof.

### Claim 125 (depends on 117)

The antibody of claim 117, wherein the antibody is linked or associated with an effector molecule.

### Claim 126 (depends on 125)

The antibody of claim 125, wherein the effector molecule is an IL-2 mutein or an anti-PD1 antibody agonist.

### Claim 127 (depends on 126)

The antibody of claim 126, wherein the IL-2 mutein comprises one or more mutations of E15Q, H16N, Q22E, D84N, E95Q, Q126E, N29S, Y31S, Y31H, K35R, T37A, K48E, N71R, L53I, L56I, L80I, L118I, V69A, Q74P, N88D, N88R, C125A or C125S.

### Claim 128

The antibody of 126, wherein the IL-2 mutein is fused or linked to a Fc peptide.

### Claim 129 (depends on 2, 126)

The antibody of claim 126, wherein the antibody linked to the effector molecule comprises a first polypeptide chain and a second a polypeptide chain that form a targeted effector polypeptide, wherein
the first chain comprises a polypeptide having the formula of:
VH-Hc-Linker-C1, wherein:
VH is the heavy chain variable domain of the antibody of claim 2;
Hc is a heavy chain constant domain;
Linker is a glycine/serine linker; and
C1 is an IL-2 mutein fused or linked to a Fc protein, wherein the Fc protein is fused or linked at the N-terminus or the C-terminus of the IL-2 mutein; and
the second chain comprises a polypeptide having the formula of VL-Lc, wherein:
VL is a light chain variable domain of the antibody of claim 2;
and Lc domain is a kappa light chain constant domain.

### Claim 130 (depends on 2)

A polypeptide having a formula of:
Ab-ConstantDomain-LinkerA-IL2Mutein-LinkerB-FcRegion,
wherein:
Ab is a heavy chain variable region of the antibody of claim 2;
ConstantDomain is an IgG constant domain;
Linker A is a peptide linker;
IL2Mutein is an IL-2 mutein;
Linker B is a peptide linker; and
FcRegion is a Fc region.

### Claim 131 (depends on 130)

The polypeptide of claim 130, wherein:
the heavy chain variable region is a heavy chain variable region of Clone ID: 6, 75, or 79 of Table 7, or any variant thereof;
the heavy chain variable region comprises the CDRs of the heavy chain variable domain of Clone 6, 75, or 79 of Table 7, or any variant thereof; or
the heavy chain variable region comprises a sequence of SEQ ID NO: 414, SEQ ID NO: 591, or SEQ ID NO: 599, or any variant thereof.

### Claim 132 (depends on 130)

The polypeptide of claim 130, wherein the heavy chain variable region comprises:
a first CDR of SEQ ID NO: 90, a second CDR of SEQ ID NO: 91, and a third CDR of SEQ ID NO: 92, or any variant thereof;
a first CDR of SEQ ID NO: 359, a second CDR of SEQ ID NO: 170, and a third CDR of SEQ ID NO: 360, or any variant thereof; or
a first CDR of SEQ ID NO: 135, a second CDR of SEQ ID NO: 381, and a third CDR of SEQ ID NO: 382, or any variant thereof.

### Claim 133 (depends on 130)

The polypeptide of claim 130, wherein the IL-2 mutein comprises a sequence of any one of SEQ ID NOs: 32, 33, 34, 35, 36, 37, 38, 39, 40, or 41.

### Claim 134 (depends on 130)

The polypeptide of claim 130, wherein the FcRegion comprises a peptide of having a sequence of SEQ ID NO: 21 or SEQ ID NO: 28.

### Claim 135 (depends on 2, 130)

The polypeptide of claim 130, wherein the polypeptide comprises a second polypeptide having a formula of VL-ConstantDomainLight, wherein the VL is a light chain variable domain of the antibody of claim 2 and the ConstantDomainLight is a IgG light chain constant domain.

### Claim 136 (depends on 135)

The polypeptide of claim 135, wherein the VL comprises a sequence of SEQ ID NO: 415, SEQ ID NO: 592, or SEQ ID NO: 600, or any variant thereof.

### Claim 137 (depends on 135)

The polypeptide of claim 135, wherein the VL comprises:
a first CDR of SEQ ID NO: 93, a second CDR of SEQ ID NO: 87, and a third CDR of SEQ ID NO: 94;
a first CDR of SEQ ID NO: 361, a second CDR of SEQ ID NO: 362, and a third CDR of SEQ ID NO: 363; or
a first CDR of SEQ ID NO: 383, a second CDR of SEQ ID NO: 384, and a third CDR of SEQ ID NO: 385.

### Claim 138 (depends on 135)

The polypeptide of claim 135, wherein the ConstantDomainLight comprises a sequence of SEQ ID NO: 45.

### Claim 139 (depends on 1)

A pharmaceutical composition comprising the antibody of claim 1.

### Claim 140 (depends on 126)

A method of treating a subject with a disorder the method comprising administering the antibody of claim 126 to the subject to treat the disorder, wherein the disorder is inflammatory bowel disease, Crohn's disease, ulcerative colitis, auto-immune hepatitis, primary sclerosing cholangitis, Type 1 diabetes, GVHD, or other auto-immune disorder described herein.

### Claim 141 (depends on 1)

A cell comprising a nucleic acid molecule encoding the antibody of claim 1.

### Claim 142

A polypeptide comprising:
i) a peptide comprising a sequence of SEQ ID NO: 90, 91, 92, 93, 94, 170, 359, 360, 361, 362, 363, 135, 381, 382, 383, 384, or 385, or any variant of the foregoing;
ii) a peptide comprising a sequence of SEQ ID NOs: 90, 91, 92, 93, 87, and 94, or any variant of any of the foregoing;
iii) a peptide comprising a sequence of SEQ ID NOs: 135, 381, 382, 383, 384, and 385, or any variant of any of the foregoing;
iv) a peptide comprising a sequence of SEQ ID NOs: 359, 170, 360, 361, 362, and 363, or any variant of any of the foregoing;
v) a peptide comprising a sequence of SEQ ID NOs: 90, 91, and 92, or any variant of any of the foregoing;
vi) a peptide comprising a sequence of SEQ ID NOs: 93, 87, and 94, or any variant of any of the foregoing;
vii) a peptide comprising a sequence of SEQ ID NOs: 135, 381, and 382 or any variant of any of the foregoing;
viii) a peptide comprising a sequence of SEQ ID NOs: 383, 384, and 385, or any variant of any of the foregoing;
ix) a peptide comprising a sequence of SEQ ID NOs: 359, 170, and 360, or any variant of any of the foregoing; or
x) a peptide comprising a sequence of SEQ ID NOs: 361, 362, and 363, or any variant of any of the foregoing.

### Claim 143 (depends on 142)

The polypeptide of claim 142 linked to a IL-2 mutein or an anti-PD-1 antibody agonist.

### Claim 144 (depends on 143)

A pharmaceutical composition comprising the polypeptide of claim 143.
